Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Identify HLA-A1101-restricted Peptide Epitopes Derived From Novel Oncoantigens (URLC10, KIF20A, and CDCA1) Applicable for Cancer Vaccine in Singapore

NCT01570439 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT01570439
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01570439 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Identify HLA-A1101-restricted Peptide Epitopes Derived From Novel Oncoantigens (URLC10, KIF20A, and CDCA1) Applicable for Cancer Vaccine in Singapore
Lead sponsor
National University Hospital, Singapore
Phase
Observational
Overall status
Unknown status
Start date
January 31, 2012
Completion date
Not reported
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anonymous donors at blood donation center (nuh)